IL98881A - Esters of 2-amino-6-alkoxyl-9-(beta-d-arabinofuranosyl)-9h-purine derivatives their preparation and immunomodulating compositions containing them - Google Patents

Esters of 2-amino-6-alkoxyl-9-(beta-d-arabinofuranosyl)-9h-purine derivatives their preparation and immunomodulating compositions containing them

Info

Publication number: IL98881A
Authority: IL; Israel
Prior art keywords: amino; purine; mmol; methoxy; arabinofuranosyl
Prior art date: 1990-07-19

Application number

IL9888191A

Other languages

English (en)

Other versions

IL98881A0 (en

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-07-19

Filing date

1991-07-18

Publication date

1996-01-19

1991-07-18 Application filed by Wellcome Found filed Critical Wellcome Found

1992-07-15 Publication of IL98881A0 publication Critical patent/IL98881A0/xx

1996-01-19 Publication of IL98881A publication Critical patent/IL98881A/en

Links

150000002148 esters Chemical class 0.000 title claims abstract description 24
238000002360 preparation method Methods 0.000 title claims abstract description 7
239000000203 mixture Substances 0.000 title description 57
230000002519 immonomodulatory effect Effects 0.000 title description 3
229940083251 peripheral vasodilators purine derivative Drugs 0.000 title description 2
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
206010028980 Neoplasm Diseases 0.000 claims abstract description 5
238000002560 therapeutic procedure Methods 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 13
239000002775 capsule Substances 0.000 claims description 9
108090000790 Enzymes Proteins 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
230000032050 esterification Effects 0.000 claims description 5
238000005886 esterification reaction Methods 0.000 claims description 5
230000000259 anti-tumor effect Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
241000894007 species Species 0.000 claims 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 165
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 46
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
239000004480 active ingredient Substances 0.000 description 44
239000000741 silica gel Substances 0.000 description 44
229910002027 silica gel Inorganic materials 0.000 description 44
238000009472 formulation Methods 0.000 description 42
239000000047 product Substances 0.000 description 41
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 34
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 31
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
150000001875 compounds Chemical class 0.000 description 29
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
239000000243 solution Substances 0.000 description 28
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
239000011541 reaction mixture Substances 0.000 description 24
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
239000007787 solid Substances 0.000 description 21
239000003921 oil Substances 0.000 description 20
238000005481 NMR spectroscopy Methods 0.000 description 19
239000000463 material Substances 0.000 description 19
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
229910052786 argon Inorganic materials 0.000 description 17
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
239000007858 starting material Substances 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
238000001035 drying Methods 0.000 description 14
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
239000004615 ingredient Substances 0.000 description 13
239000000843 powder Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
238000003756 stirring Methods 0.000 description 13
239000003826 tablet Substances 0.000 description 13
101150041968 CDC13 gene Proteins 0.000 description 12
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
210000001744 T-lymphocyte Anatomy 0.000 description 10
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
229940086542 triethylamine Drugs 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 9
239000000706 filtrate Substances 0.000 description 9
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
239000007788 liquid Substances 0.000 description 9
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
229940069328 povidone Drugs 0.000 description 9
238000011282 treatment Methods 0.000 description 9
210000002700 urine Anatomy 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000012043 crude product Substances 0.000 description 8
239000008101 lactose Substances 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 8
239000012044 organic layer Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
101150084021 araG gene Proteins 0.000 description 6
239000006071 cream Substances 0.000 description 6
NYHBQMYGNKIUIF-FJFJXFQQSA-N 9-beta-D-arabinofuranosylguanine Chemical compound C12=NC(N)=NC(O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O NYHBQMYGNKIUIF-FJFJXFQQSA-N 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
238000007792 addition Methods 0.000 description 5
-1 arabinofuranosyl purine derivatives Chemical class 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
239000003925 fat Substances 0.000 description 5
235000019197 fats Nutrition 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
229940080313 sodium starch Drugs 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
108090000787 Subtilisin Proteins 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
239000008213 purified water Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
XHAXVDWUMCHTCY-UHFFFAOYSA-N 2,2,2-trichloroethyl acetate Chemical compound CC(=O)OCC(Cl)(Cl)Cl XHAXVDWUMCHTCY-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000010549 co-Evaporation Methods 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 2
MEFWWUOADZDECZ-UHFFFAOYSA-N 2,2,2-trichloroethyl propanoate Chemical compound CCC(=O)OCC(Cl)(Cl)Cl MEFWWUOADZDECZ-UHFFFAOYSA-N 0.000 description 2
NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 2
PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000000465 moulding Methods 0.000 description 2
201000006938 muscular dystrophy Diseases 0.000 description 2
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
IXOXBSCIXZEQEQ-KBNQYOMWSA-N (3s,4s,5r)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1C1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-KBNQYOMWSA-N 0.000 description 1
QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
QKIJJNFIBPAIMD-UHFFFAOYSA-N 1-o-methyl 4-o-(2,2,2-trichloroethyl) butanedioate Chemical compound COC(=O)CCC(=O)OCC(Cl)(Cl)Cl QKIJJNFIBPAIMD-UHFFFAOYSA-N 0.000 description 1
LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
NTNMPDQKBQRDHQ-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-5-methylpyrazol-3-amine Chemical compound N1=C(C)C=C(N)N1C1=NC2=CC=CC=C2N1 NTNMPDQKBQRDHQ-UHFFFAOYSA-N 0.000 description 1
ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000594820 Homo sapiens Purine nucleoside phosphorylase Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229940040526 anhydrous sodium acetate Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
JEPAHPFDUXQBAO-FJFJXFQQSA-N arabinofuranosylguanine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=N)N=C2O)=C2N[CH]1 JEPAHPFDUXQBAO-FJFJXFQQSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
229940078545 isocetyl stearate Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940054534 ophthalmic solution Drugs 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
239000008251 pharmaceutical emulsion Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Earth Drilling (AREA)
Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Stereophonic System (AREA)

IL9888191A 1990-07-19 1991-07-18 Esters of 2-amino-6-alkoxyl-9-(beta-d-arabinofuranosyl)-9h-purine derivatives their preparation and immunomodulating compositions containing them IL98881A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909015914A GB9015914D0 (en)	1990-07-19	1990-07-19	Heterocyclic compounds

Publications (2)

Publication Number	Publication Date
IL98881A0 IL98881A0 (en)	1992-07-15
IL98881A true IL98881A (en)	1996-01-19

Family

ID=10679359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9888191A IL98881A (en)	1990-07-19	1991-07-18	Esters of 2-amino-6-alkoxyl-9-(beta-d-arabinofuranosyl)-9h-purine derivatives their preparation and immunomodulating compositions containing them

Country Status (23)

Country	Link
US (3)	US5492897A (de)
EP (1)	EP0539479B1 (de)
JP (1)	JP2873086B2 (de)
KR (1)	KR100187326B1 (de)
AT (1)	ATE151637T1 (de)
CA (1)	CA2087543C (de)
CY (1)	CY2165B1 (de)
DE (1)	DE69125715T2 (de)
DK (1)	DK0539479T3 (de)
ES (1)	ES2103311T3 (de)
GB (1)	GB9015914D0 (de)
GR (1)	GR3023776T3 (de)
HU (2)	HU9300115D0 (de)
IE (1)	IE912513A1 (de)
IL (1)	IL98881A (de)
MC (1)	MC2289A1 (de)
MY (1)	MY111871A (de)
NZ (1)	NZ239025A (de)
PT (1)	PT98371B (de)
RU (1)	RU2114860C1 (de)
TW (1)	TW208655B (de)
WO (1)	WO1992001456A1 (de)
ZA (1)	ZA915656B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9015914D0 (en) *	1990-07-19	1990-09-05	Wellcome Found	Heterocyclic compounds
AU6771198A (en) *	1997-03-24	1998-10-20	Glaxo Group Limited	Method for treating b-cell tumors with ara-g nucleoside derivatives
EP1092435B1 (de) *	1998-07-02	2007-04-04	Kyowa Hakko Kogyo Co., Ltd.	Antidiabetische medikamente
US6753322B2 (en) *	2000-06-06	2004-06-22	Pfizer Inc	2-aminocarbonyl-9H-purine derivatives
AP2004003069A0 (en)	2001-11-27	2004-06-30	Anadys Pharmaceuticals Inc	3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
US7321033B2 (en) *	2001-11-27	2008-01-22	Anadys Pharmaceuticals, Inc.	3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2003261354A1 (en) *	2002-08-02	2004-02-23	The Regents Of The University Of California	New uses for inhibitors of inosine monophosphate dehydrogenase
JP2007504232A (ja) *	2003-09-05	2007-03-01	アナディスファーマシューティカルズインク	Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
GB0321613D0 (en) *	2003-09-15	2003-10-15	Drug Discovery Lab As	Compounds
EP1804838A2 (de) *	2004-09-15	2007-07-11	Drug Discovery Laboratory AS	Arzneikonjugate einer langkettigen fettsäure oder ester-reste als proteinbindende prodrugs
US20090082304A1 (en) *	2004-11-12	2009-03-26	Northwestern University	Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs
US7560544B2 (en)	2004-12-17	2009-07-14	Anadys Pharmaceuticals, Inc.	3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US20060189543A1 (en) *	2005-02-23	2006-08-24	Rosenbloom Richard A	Compositions and methods for the treatment of leukemia
DE602006015700D1 (de)	2005-11-21	2010-09-02	Anadys Pharmaceuticals Inc	Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
KR101461604B1 (ko) *	2006-06-22	2014-11-18	애나디스 파마슈티칼스, 인코포레이티드	5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
WO2008011406A2 (en)	2006-07-18	2008-01-24	Anadys Pharmaceuticals, Inc.	Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
CN101768197A (zh) *	2008-12-29	2010-07-07	北京德众万全药物技术开发有限公司	一种奈拉滨的制备方法
EP2658857B1 (de) *	2010-12-29	2016-11-02	Inhibitex, Inc.	Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
WO2018230479A1 (ja) *	2017-06-13	2018-12-20	大原薬品工業株式会社	ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体
KR102918401B1 (ko) *	2020-12-30	2026-01-26	서던 유니버시티 오브 사이언스 앤드 테크놀로지	코로나 바이러스 감염을 치료하기 위한 방법 및 변형된 뉴클레오사이드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2152486A1 (de)	1970-11-20	1972-06-29	Akad Wissenschaften Ddr	Verfahren zur Herstellung von 5'-Desoxy-5'-fluor-6-methyl-mercaptopurinribosid
US3872084A (en) *	1972-10-10	1975-03-18	Syntex Inc	Purine nucleoside 3,5-cyclicphosphate compounds
US4081534A (en) *	1973-09-11	1978-03-28	Burroughs Wellcome Co.	Amino purine nucleosides as autoimmune suppressant agents
GB1573777A (en) *	1977-11-03	1980-08-28	Wellcome Found	9-d-arabinonucleosides and an enzymatic process for their preparation
JPS61233696A (ja) *	1985-04-08	1986-10-17	Kanegafuchi Chem Ind Co Ltd	７−ヒドロキシグアニン誘導体及びその製造方法並びにそれを有効成分とする抗腫瘍剤
JPH0633263B2 (ja) *	1985-05-27	1994-05-02	鐘淵化学工業株式会社	７−ヒドロキシグアニン誘導体及びその製造方法並びにそれを有効成分とする抗腫瘍剤
GB8712745D0 (en) *	1987-05-30	1987-07-01	Wellcome Found	Antiviral compounds
CA1317291C (en) *	1987-12-14	1993-05-04	Naeem Botros Hanna	Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds
US5352669A (en) *	1990-03-13	1994-10-04	The Of The United States Of America As Represented By The Department Of Health And Human Services	O6 -benzylated guanine, guanosine and 2'-deoxyguanosine compounds possessing O6 -alkylguanine-DNA alkyltransferase depleting activity
GB9015914D0 (en) *	1990-07-19	1990-09-05	Wellcome Found	Heterocyclic compounds

1990
- 1990-07-19 GB GB909015914A patent/GB9015914D0/en active Pending
1991
- 1991-07-18 ES ES91913553T patent/ES2103311T3/es not_active Expired - Lifetime
- 1991-07-18 IL IL9888191A patent/IL98881A/en not_active IP Right Cessation
- 1991-07-18 DE DE69125715T patent/DE69125715T2/de not_active Expired - Lifetime
- 1991-07-18 EP EP91913553A patent/EP0539479B1/de not_active Expired - Lifetime
- 1991-07-18 HU HU93115A patent/HU9300115D0/hu unknown
- 1991-07-18 KR KR1019930700144A patent/KR100187326B1/ko not_active Expired - Lifetime
- 1991-07-18 IE IE251391A patent/IE912513A1/en unknown
- 1991-07-18 DK DK91913553.3T patent/DK0539479T3/da active
- 1991-07-18 RU RU93004860A patent/RU2114860C1/ru active Protection Beyond IP Right Term
- 1991-07-18 AT AT91913553T patent/ATE151637T1/de not_active IP Right Cessation
- 1991-07-18 MY MYPI91001298A patent/MY111871A/en unknown
- 1991-07-18 CA CA002087543A patent/CA2087543C/en not_active Expired - Lifetime
- 1991-07-18 ZA ZA915656A patent/ZA915656B/xx unknown
- 1991-07-18 PT PT98371A patent/PT98371B/pt not_active IP Right Cessation
- 1991-07-18 JP JP3512249A patent/JP2873086B2/ja not_active Expired - Lifetime
- 1991-07-18 NZ NZ239025A patent/NZ239025A/en not_active IP Right Cessation
- 1991-07-18 MC MC91@@D patent/MC2289A1/xx unknown
- 1991-07-18 HU HU93115D patent/HUT62911A/hu unknown
- 1991-07-18 WO PCT/GB1991/001196 patent/WO1992001456A1/en not_active Ceased
- 1991-07-27 TW TW080105920A patent/TW208655B/zh not_active IP Right Cessation
1994
- 1994-04-07 US US08/224,343 patent/US5492897A/en not_active Expired - Lifetime
1995
- 1995-05-24 US US08/449,078 patent/US5821236A/en not_active Expired - Lifetime
- 1995-05-31 US US08/456,186 patent/US5747472A/en not_active Expired - Lifetime
1997
- 1997-06-12 GR GR970401414T patent/GR3023776T3/el unknown
2000
- 2000-04-10 CY CY0000009A patent/CY2165B1/xx unknown

Also Published As

Publication number	Publication date
CA2087543C (en)	1998-08-25
MY111871A (en)	2001-02-28
US5747472A (en)	1998-05-05
IE912513A1 (en)	1992-01-29
EP0539479A1 (de)	1993-05-05
WO1992001456A1 (en)	1992-02-06
RU2114860C1 (ru)	1998-07-10
HUT62911A (en)	1993-06-28
PT98371A (pt)	1992-06-30
DE69125715T2 (de)	1997-08-07
DE69125715D1 (de)	1997-05-22
NZ239025A (en)	1993-08-26
DK0539479T3 (da)	1997-08-25
GR3023776T3 (en)	1997-09-30
CA2087543A1 (en)	1992-01-20
MC2289A1 (fr)	1993-07-14
KR100187326B1 (ko)	1999-05-01
PT98371B (pt)	1999-01-29
CY2165B1 (en)	2002-08-23
IL98881A0 (en)	1992-07-15
ZA915656B (en)	1993-03-31
AU641533B2 (en)	1993-09-23
JPH05508649A (ja)	1993-12-02
ES2103311T3 (es)	1997-09-16
US5492897A (en)	1996-02-20
GB9015914D0 (en)	1990-09-05
ATE151637T1 (de)	1997-05-15
EP0539479B1 (de)	1997-04-16
US5821236A (en)	1998-10-13
AU8196091A (en)	1992-02-18
TW208655B (de)	1993-07-01
JP2873086B2 (ja)	1999-03-24
HU9300115D0 (en)	1993-04-28

Legal Events

Date	Code	Title
1996-06-18	FF	Patent granted
1998-01-04	KB	Patent renewed
2001-10-31	KB	Patent renewed
2005-09-25	KB	Patent renewed
2010-02-14	KB	Patent renewed
2012-02-29	EXP	Patent expired

Publication	Publication Date	Title
US5821236A (en)	1998-10-13	Tumor treatment with arabinofuranosyl purine derivatives
US5424295A (en)	1995-06-13	9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
JP3933870B2 (ja)	2007-06-20	２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
US5208241A (en)	1993-05-04	N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5547941A (en)	1996-08-20	Cyclic dinucleoside diphosphorothioates, related compounds and pharmaceutical compositions
US5032583A (en)	1991-07-16	2,N-6-disubstituted adenosines and their antihypertensive methods of use
KR20010031875A (ko)	2001-04-16	화학 화합물
JPH03209386A (ja)	1991-09-12	免疫抑制活性を有するアミノマクロライドおよび誘導体
JPH09508144A (ja)	1997-08-19	抗真菌ソルダリン誘導体
KR20180134835A (ko)	2018-12-19	5-아자사이티딘류의 당 부분(糖部) 실릴에테르 유도체
HK1005738A1 (en)	1999-01-22	Griseolic acid derivatives, their preparation and their use
HK1005738B (en)	1999-01-22	Griseolic acid derivatives, their preparation and their use
EP0061283A1 (de)	1982-09-29	Antivirale Verbindungen, ihre Herstellung und Anwendung
EP0362967A1 (de)	1990-04-11	Nukleosid-Derivate
AU641533C (en)	1994-06-09	Heterocyclic compounds
EP0104857A1 (de)	1984-04-04	Deoxyuridin-Derivate, Verfahren zu deren Herstellung und ihre Verwendung in der Medizin
US4992534A (en)	1991-02-12	3'-O-,5'-O-derivatives of 2'-deoxy-5-fluorouridine
CN117603286A (zh)	2024-02-27	一种溶酶体靶向的衰老细胞清除前药的制备及应用
EP0450102A1 (de)	1991-10-09	Nukleosidderivate
EP0097039A1 (de)	1983-12-28	5-(E-2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zur Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen
Byun et al.	1995	A short synthesis of antitumor ether thioglycolipids: Thioglycosidation of a glucose donor with a tributylstannyl sulfide acceptor
EP0319050B1 (de)	1995-04-12	Griseolsäurederivate, ihre Herstellung und ihre Verwendung
EP0492430A1 (de)	1992-07-01	Oxetanocinderivate mit Imidazolbasisgruppe
JPH09316093A (ja)	1997-12-09	ポリリン酸誘導体
EP0095292A1 (de)	1983-11-30	5-(2-Halovinyl)-2'-deoxyuridin-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Anwendung bei der Behandlung von viralen Infektionen